KEGG   DRUG: Tocilizumab
Entry
D02596                      Drug                                   
Name
Tocilizumab (USAN/INN);
Tocilizumab (genetical recombination) (JAN);
Tocilizumab-aazg;
Tocilizumab-bavi;
Actemra (TN);
Tofidence (TN);
Tyenne (TN)
Product
TOCILIZUMAB (Genentech), TOFIDENCE (Biogen MA), TYENNE (Fresenius Kabi USA), TYENNE (Fresenius Kabi USA)
Formula
C6428H9976N1720O2018S42
Exact mass
144895.9145
Mol weight
144985.11
Class
Immunological agent
 DG02019  Interleukin inhibitor
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
Remark
Therapeutic category: 6399
ATC code: L04AC07
Product: D02596<JP/US>
Efficacy
Anti-inflammatory, Antirheumatic, Immunosuppressant, Anti-IL-6 receptor antibody
  Disease
Rheumatoid arthritis [DS:H00630]
Giant Cell Arteritis [DS:H01698]
Systemic sclerosis-associated interstitial lung disease [DS:H01492]
Polyarticular juvenile idiopathic arthritis [DS:H01672]
Systemic juvenile idiopathic arthritis [DS:H01672]
Coronavirus disease 2019 [DS:H02398]
  Type
Monoclonal antibody
Comment
Treatment of cytokine release syndrome
Target
IL6R (CD126) [HSA:3570] [KO:K05055]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
hsa04640  Hematopoietic cell lineage
Interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC07 Tocilizumab
      D02596  Tocilizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Tocilizumab
     D02596  Tocilizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D02596  Tocilizumab (USAN/INN); Tocilizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D02596  Tocilizumab
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D02596  Tocilizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D02596  Tocilizumab
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D02596  Tocilizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL6R (CD126)
     D02596  Tocilizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D02596
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02596
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02596
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D02596
Other DBs
CAS: 375823-41-9
PubChem: 17396767
NIKKAJI: J2.104.935B
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system